[lcus_masonry_article] Case Study: A Diabetes-Focused Partner Uses the Cure Discovery to De-Risk Lead Selection A company with a diabetes and metabolic pipeline was looking for cure-focused compounds—not another glucose management asset—with validated discovery scores, synthesis methods, and scientific evidence aligned with known mechanisms (e.g. zinc–amino acid complexes, insulin signaling). They had development capacity; they needed […]
content by LCUS
Product Insight – From Management to Cure, What to Ask When the Asset Is Cure-Focused
[lcus_masonry_article] Product Insight: From Management to Cure—What to Ask When the Asset Is Cure-Focused Diabetes treatment has advanced enormously, but the dominant paradigm remains management. The Diabetes Cure Discovery product shifts the frame: validated, cure-focused compounds (Alchemy Data V2), a top candidate (e.g. C-H-O-N-Zn) with discovery scores, synthesis methods, and scientific evidence aligned with known […]